Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-1019 in Advanced Solid Tumors
NCT05830097Phase 2Recruiting
- Sponsor
- Coherent Biopharma
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Cytotoxic ADCs, Small Molecules, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of CBP-1019 in solid tumor (advanced stage), lung cancer, pancreatic cancer (PC) and 3 more, sponsored by Coherent Biopharma. Primary endpoint: Incidence and severity of Adverse Events at 12 months. Started Mar 2023; status: recruiting.
02
Drugs
CBP-1019
03
Conditions
solid tumor (advanced stage)lung cancerpancreatic cancer (PC)colorectal cancer (CRC)esophageal cancer
Beyond the preview
Go deeper on NCT05830097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830097.